SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ARIAD Pharmaceuticals
An SI Board Since September 1996
Posts SubjectMarks Bans Symbol
4474 134 0 ARIA
Emcee:  jaybe Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
4324MSK & Nature That's some real street cred -- not just your garden-varieglass 0.5 full-6/23/2016
4323MSKCC finds synergy with pona and trametinib in KRASm lung cancer... "We njaybe-6/22/2016
4322Why are you so upset? I know you had a bad today, we all did. No reason to taktestad-6/17/2016
4321There is no Mr. Market when it comes to ARIA,just HedgeScums, GS and MM who havecivic08801-6/17/2016
4320Well if that was the answer, Mr. market was not impressed.testad-6/17/2016
4319And the answer is>> investor.ariad.comcivic08801-6/17/2016
4318He may be a "real pro", but I'm not sure how this makes him a &quotestad-6/17/2016
4317finance.yahoo.comcivic08801-6/17/2016
4316Can you elaborate on that a little? What makes you say that?testad-6/17/2016
4315ARIA News Denner is a real procivic08801-6/17/2016
4314Ariad's CMLrisks.com website outlines case for use of most potent TKI in 2L.jaybe-6/13/2016
4313Pona posters from EHA 2016 available at Incyte (fka Ariad)... ariadnordics.eu jaybe-6/11/2016
4312Definitely not. The biggest and most important differentiator with alectinib isjaybe26/10/2016
4311Jaybe, is Alectinib fairly even with Brigatinib in all categories other than CNSjesspro-6/10/2016
4310I think the space is going to end up as a fight between alectinib and briga for Biomaven-6/10/2016
4309A more detailed breakdown is needed since lorlatinib included responses from higjaybe16/9/2016
4308If you compare only the patients with a single prior TKI, the drugs look pretty Biomaven-6/9/2016
4307A few slides from lorlatinib (PF-06463922) presentation at ASCO... Still comingjaybe16/8/2016
4306MSKCC poster finds 20% of EGFRm lung cancer with rare mutations... Exon 20 at 1jaybe36/7/2016
4305Well the real issue that delayed the trials was the issue of early pulmonary symBiomaven26/7/2016
4304Yes, Criz is currently the only approved first line agent for ALK+, which is whytktom-6/7/2016
4303Yes, Criz is currently the only approved first line agent for ALK+, which is whyBiomaven16/7/2016
4302Peter please correct me if I am wrong but isn't Criz first line? Tx Scottyosarian_2-6/7/2016
4301I would assume the PR in the patient without a detectable mutation had tumors ofBiomaven16/7/2016
4300Since quite a number of patients with NSCLC have no known mutation driving theirGregorioAllegri-6/7/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News